INTRODUCTION: Sarcopenia is defined as the loss of muscle mass and muscular functioning. Although sarcopenia prevalence is highly variable in the literature, pre-chemotherapy sarcopenia prevalence was not well studied in newly diagnosed cancer patients. In this context, the present study aims to determine the prevalence of sarcopenia and its related factors in this population. MATERIAL AND METHODS: Prospectively, newly diagnosed cancer patients were evaluated for body composition measurement and muscle strength by employing the bioelectric impedance analysis method and handgrip dynamometer tool. RESULTS: A total of 461 patients were included in the study. The median age of patients was 59 years (range 18-83) and 258 patients (56%) were women. Sarcopenia was present in 77 patients (16.7%) and was at significantly higher frequencies in men (p = 0.015), advanced age (≥ 65 years, p = 0.014), lower body mass index (BMI < 25, p = < 0.001), and poor performance status (ECOG status > 0, p = 0.026). In multivariate analyses, advanced age (over 65 years), gender (men), and lower body mass index (BMI < 25) were significantly associated with sarcopenia (p values 0.033, < 0.001, and < 0.001, respectively). CONCLUSIONS: Our study is the first prevalence study conducted with bioelectric impedance analysis on Turkish cancer patients and sarcopenia was detected to be notably prevalent among our patients with newly diagnosed cancer. Given the likely negative outcomes of sarcopenia reported in the literature (treatment failure, increased complications, and impaired survival), it is important to know the presence of sarcopenia before treatment and take preventive precautions.
INTRODUCTION:Sarcopenia is defined as the loss of muscle mass and muscular functioning. Although sarcopenia prevalence is highly variable in the literature, pre-chemotherapy sarcopenia prevalence was not well studied in newly diagnosed cancerpatients. In this context, the present study aims to determine the prevalence of sarcopenia and its related factors in this population. MATERIAL AND METHODS: Prospectively, newly diagnosed cancerpatients were evaluated for body composition measurement and muscle strength by employing the bioelectric impedance analysis method and handgrip dynamometer tool. RESULTS: A total of 461 patients were included in the study. The median age of patients was 59 years (range 18-83) and 258 patients (56%) were women. Sarcopenia was present in 77 patients (16.7%) and was at significantly higher frequencies in men (p = 0.015), advanced age (≥ 65 years, p = 0.014), lower body mass index (BMI < 25, p = < 0.001), and poor performance status (ECOG status > 0, p = 0.026). In multivariate analyses, advanced age (over 65 years), gender (men), and lower body mass index (BMI < 25) were significantly associated with sarcopenia (p values 0.033, < 0.001, and < 0.001, respectively). CONCLUSIONS: Our study is the first prevalence study conducted with bioelectric impedance analysis on Turkish cancerpatients and sarcopenia was detected to be notably prevalent among our patients with newly diagnosed cancer. Given the likely negative outcomes of sarcopenia reported in the literature (treatment failure, increased complications, and impaired survival), it is important to know the presence of sarcopenia before treatment and take preventive precautions.
Authors: R N Baumgartner; K M Koehler; D Gallagher; L Romero; S B Heymsfield; R R Ross; P J Garry; R D Lindeman Journal: Am J Epidemiol Date: 1998-04-15 Impact factor: 4.897
Authors: T Cederholm; R Barazzoni; P Austin; P Ballmer; G Biolo; S C Bischoff; C Compher; I Correia; T Higashiguchi; M Holst; G L Jensen; A Malone; M Muscaritoli; I Nyulasi; M Pirlich; E Rothenberg; K Schindler; S M Schneider; M A E de van der Schueren; C Sieber; L Valentini; J C Yu; A Van Gossum; P Singer Journal: Clin Nutr Date: 2016-09-14 Impact factor: 7.324
Authors: Roger A Fielding; Bruno Vellas; William J Evans; Shalender Bhasin; John E Morley; Anne B Newman; Gabor Abellan van Kan; Sandrine Andrieu; Juergen Bauer; Denis Breuille; Tommy Cederholm; Julie Chandler; Capucine De Meynard; Lorenzo Donini; Tamara Harris; Aimo Kannt; Florence Keime Guibert; Graziano Onder; Dimitris Papanicolaou; Yves Rolland; Daniel Rooks; Cornel Sieber; Elisabeth Souhami; Sjors Verlaan; Mauro Zamboni Journal: J Am Med Dir Assoc Date: 2011-03-04 Impact factor: 4.669
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12 Impact factor: 5.837